{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134238","form_type":"8-K","ticker":"CTKB","cik":"0001831915","company_name":"Cytek Biosciences, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.545353+00:00","generated_at":"2026-06-02T12:53:30.513263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance","bullets":["Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.","Gross profit margin 51% (down from 57%); adjusted gross margin 55% (down from 59%).","Net loss $6.2M vs $6.8M loss; Adjusted EBITDA loss $0.7M vs $2.5M loss.","Reaffirms 2024 revenue guidance $203M-$213M (5-10% growth); expects positive net income for FY2024.","Appointed William McCombe as CFO; opened new facility in Wuxi, China; received NMPA approvals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134238","json":"https://secwatch.observer/filing/0001193125-24-134238.json","markdown":"https://secwatch.observer/filing/0001193125-24-134238.md","text":"https://secwatch.observer/filing/0001193125-24-134238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/0001193125-24-134238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/d814789d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:53:30.513263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cd2dc86b6d6212d931e163fb242e390d11fbad7a","claim":"Cytek Biosciences, Inc. reported the quarter ended March 31, 2024 results: revenue $44.9 million, net income $6.2 million. Guidance reaffirmed.","evidence_excerpt":"(Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase over the corresponding period of 2023 • Organic revenue was $37.3 million, representing an increase of 11% compared to the first quarter of 2023 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831915/000119312524134238/0001193125-24-134238-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$44.9 million"},{"label":"Net income","value":"$6.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}